Middletown, NJNCT04872543Now EnrollingIRB Ready

Malignant Peripheral Nerve Sheath Tumors Clinical Trial in Middletown, NJ

Access cutting-edge malignant peripheral nerve sheath tumors treatment through this clinical trial at a research site in Middletown. Study-provided care at no cost to qualified participants.

Sponsored by Memorial Sloan Kettering Cancer Center

Quick Self-Assessment

See if you qualify for this Middletown location

Preparing your pre-screening questions...

Expert Care in Middletown

Access malignant peripheral nerve sheath tumors specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related malignant peripheral nerve sheath tumors treatment provided free

Apply for This Middletown Location

Check if you qualify for this malignant peripheral nerve sheath tumors clinical trial in Middletown, NJ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Middletown

    Convenient for NJ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Middletown site if eligible
  4. 4Begin participation

About This Malignant Peripheral Nerve Sheath Tumors Study in Middletown

The purpose of this study is to see whether the study drug ASTX727 is an effective treatment for people who have MPNST with a PCR2 mutation. ASTX727 is a combination of two drugs (cedazuridine and decitabine) that have been designed to target cancer cells with a PCR2 mutation and to disrupt the cells' ability to survive and grow. The study researchers think that the study drug allows decitabine to work better than decitabine given alone.

Sponsor: Memorial Sloan Kettering Cancer Center

Who Can Participate

Inclusion Criteria

Patients must have pathologically confirmed PRC2 loss MPNSTs (e.g. IHC of loss H3K27me2 and/or H3K27me3 immunostaining, and/or inactivating mutations in EED, SUZ12, EZH2 by CLIA approved genetic assays), which are advanced, unresectable or metastatic and have progressed on at least one line of standard of care systemic therapy, or administration of cytotoxic chemotherapy is not considered in the best interest for the patient.
Patients must be at least 18 years of age
Patients must have Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.
Disease must be measurable by RECIST 1.1.
Patients must be able to take oral medications.
Patient or legally authorized representative can understand and comply with the protocol and must sign an informed consent document.
Adequate renal, hepatic and hematologic function as the following: serum creatinine ≤ 1.5 x upper limit of normal (ULN), total serum bilirubin ≤ 1.5 x ULN, serum AST (SGOT) ≤ 2.5 x UL

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Middletown?

Yes, this clinical trial (NCT04872543) has an active research site in Middletown, NJ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Malignant Peripheral Nerve Sheath Tumors Treatment Options in Middletown, NJ

If you're searching for malignant peripheral nerve sheath tumors treatment options in Middletown, NJ, this clinical trial (NCT04872543) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Middletown research site is actively enrolling participants for this clinical trial. You'll receive care from experienced malignant peripheral nerve sheath tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all malignant peripheral nerve sheath tumors clinical trials near you to find additional studies recruiting in your area.

More Pulmonary Embolism Trials in Middletown, NJ

See all pulmonary embolism clinical trials recruiting in Middletown — not just this study.

Browse Pulmonary Embolism Trials in Middletown →

Browse More Trials by Condition

Pulmonary Embolism TrialsRheumatoid Arthritis TrialsPulmonary Hypertension TrialsAll Conditions →

Ready to Join in Middletown?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Middletown, NJ